- RecruitingPHASE2, PHASE3
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
This study looks at a new drug, Navlimetostat, combined with standard treatments for advanced lung cancer. It compares this combination to standard treatments alone in patients whose cancer has a specific genetic change called an MTAP deletion. The aim is to see if the new combination works better.
For: Metastatic Non-small Cell Lung Cancer With MTAP DeletionUnited States · Argentina · Australia - RecruitingPHASE2, PHASE3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
This study is testing a new drug, iza-bren, for advanced triple-negative breast cancer or ER-low, HER2-negative breast cancer. It compares iza-bren with standard chemotherapy in patients who haven't had previous treatment for advanced disease and can't receive certain immunotherapy drugs.
For: Breast NeoplasmsUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
This study is looking at a new medicine called Dato-DXd for advanced triple-negative breast cancer. It compares Dato-DXd with standard chemotherapy in patients who cannot have a specific type of immunotherapy. The aim is to see if Dato-DXd is better at shrinking tumours and helping people live longer.
For: Breast CancerUnited States · Argentina · Belgium - Active not recruitingPHASE1
A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
This study looks at new drug combinations for treating advanced stomach, bile duct, and pancreatic cancers. It focuses on cancers with a specific genetic change (MTAP-deletion) to see how safe and effective these new treatments are.
For: Advanced Gastrointestinal, Biliary Tract, and Pancreatic CancersUnited States · Australia · Belgium - Active not recruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
This study compares a new medicine, sacituzumab tirumotecan, with standard chemotherapy for endometrial cancer. It's for people whose cancer has returned or progressed after previous treatments (platinum-based chemotherapy and immunotherapy). Researchers want to see if the new medicine helps people live longer and keeps the cancer from getting worse.
For: Endometrial CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
This study is for people with a specific type of advanced breast cancer (PD-L1 positive triple-negative) that hasn't been treated yet. It compares two different drug combinations to see which one works better at stopping the cancer from growing.
For: Triple Negative Breast Cancer · PD-L1 PositiveUnited States · Argentina · Australia - Active not recruitingPHASE3
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
This study is testing new combinations of medicines (Zimberelimab and Domvanalimab with chemotherapy) against a standard treatment (Pembrolizumab with chemotherapy) for people with advanced non-small cell lung cancer that hasn't been treated yet. We want to see which combination helps people live longer.
For: Non-small Cell Lung CancerUnited States · Argentina · Austria - RecruitingPHASE3
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
This study is for people with advanced HR+/HER2- breast cancer. It compares a new drug, sacituzumab tirumotecan (alone or with pembrolizumab), against standard chemotherapy, to see which treatment best controls the cancer's growth.
For: Breast NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE3
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
This study looks at a new drug, patritumab deruxtecan, for a certain type of advanced breast cancer. It aims to see if this new treatment helps people live longer or stops cancer from growing compared to standard treatments like chemotherapy.
For: Breast NeoplasmsUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
This study is testing a new drug, quemliclustat, alongside standard chemotherapy for pancreatic cancer that has spread. Researchers want to see if adding quemliclustat helps people live longer compared to chemotherapy alone. It's a phase 3 trial, meaning it's in the final stages of testing.
For: Metastatic Pancreatic Ductal AdenocarcinomaUnited States · Australia · Austria - RecruitingPHASE3
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
This study looks at new treatments, sacituzumab tirumotecan alone or with pembrolizumab, for triple-negative breast cancer. It compares their effectiveness with standard chemotherapy to see if they help people live longer or stop cancer growth.
For: Triple Negative Breast NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE3
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
This study is looking at a new drug, daraxonrasib, for people with pancreatic cancer that has spread. It compares daraxonrasib alone, or with standard chemotherapy (gemcitabine and nab-paclitaxel), against standard chemotherapy by itself. The aim is to see if the new treatments can help people live longer and stop the cancer from growing.
For: Pancreatic Cancer · Pancreatic Cancer Metastatic · PDACUnited States · Australia · Austria - Active not recruitingPHASE3
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
This study looks at a new drug, Sacituzumab Govitecan, for advanced breast cancer. It compares it to standard treatments to see if it can slow cancer growth or spread, helping people live longer and healthier lives.
For: Locally Advanced or Unresectable Metastatic Breast Cancer · Stage IV Breast CancerUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
This study looks at different treatment combinations for advanced breast cancer, including those that have spread or are hard to remove. Doctors want to see how well these new drug combinations work and if they are safe for patients.
For: Metastatic Breast CancerUnited States · Australia · France - Active not recruitingPHASE3
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
This study looks at a new drug, trastuzumab deruxtecan, for advanced breast cancer that is HER2-low and hormone receptor positive. We want to see if it works better and is safer than standard chemotherapy for people whose cancer has progressed after other treatments.
For: Advanced or Metastatic Breast CancerUnited States · Argentina · Australia - RecruitingPHASE3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
This study looks at new ways to treat advanced squamous non-small cell lung cancer. It combines standard treatment (Pembrolizumab, Carboplatin, Paclitaxel/Nab-paclitaxel) with a new drug, sac-TMT, to see if it helps people live longer.
For: Non-small Cell Lung Cancer · NSCLCUnited States · Argentina · Austria - RecruitingPHASE3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
This study looks at new treatments for a type of breast cancer called triple-negative. It compares a new drug, Dato-DXd, sometimes with Durvalumab, against standard chemotherapy with Pembrolizumab for patients whose cancer has come back locally or spread.
For: Breast CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
This study looks at a new drug, Sacituzumab Govitecan-hziy, for people with an aggressive type of breast cancer called triple-negative breast cancer that has spread or can't be operated on. It compares this new drug to standard treatments to see which works better at stopping the cancer from growing.
For: Triple Negative Breast Cancer · PD-L1 NegativeUnited States · Argentina · Australia - Active not recruitingPHASE1, PHASE2
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
This study is testing a new cancer medicine, GEN1042, both by itself and with other treatments. It's for people with certain advanced solid tumours where standard treatments haven't worked or aren't available. The main goals are to check its safety and see how well it fights cancer.
For: Malignant Solid Tumor · Non-Small Cell Lung Cancer (NSCLC) · Colorectal Cancer (CRC)United States · Denmark · France - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
This study looks at a new treatment for a type of breast cancer that has come back or spread. It combines a drug called pembrolizumab with standard chemotherapy to see if it works better than chemotherapy alone for HR+/HER2- breast cancer.
For: Breast NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
This study is looking at new ways to treat advanced lung cancer (squamous non-small cell lung cancer) that has spread. It compares two different drug combinations, including a new medicine called rilvegostomig, to see if they can help patients live longer and improve their quality of life.
For: Non-small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
This study is testing a new medicine called S241656 for people with certain advanced cancers, including lung, bowel, and pancreatic cancers. It aims to find a safe and effective dose, either alone or with other treatments, for cancers with specific genetic changes.
For: Non-small Cell Lung Cancer · Histiocytic Neoplasm · HistiocytosisUnited States · Australia · China - RecruitingPHASE1
CHemotherapy and Stool Transplant in PDAC (CHASe-PDAC)
This study looks at combining a stool transplant with standard chemotherapy for advanced pancreatic cancer. It's a first step to see if this new combination is safe and how patients respond, hoping to find better ways to treat the disease.
For: Unresectable or Metastatic Advanced Pancreatic Ductal AdenocarcinomaCanada - RecruitingPHASE1, PHASE2
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
This study looks at new and existing treatments for advanced lung cancer (non-small cell type). Researchers are testing different drug combinations to see how safe and effective they are. It aims to find better ways to treat this condition.
For: Advanced or Metastatic Non-small Cell Lung CancerUnited States · Belgium · Brazil - Active not recruitingPHASE3
Detect V / CHEVENDO (Chemo vs. Endo)
This study compares different treatments for advanced breast cancer that has spread. It aims to see if a combination of targeted therapies and hormone therapy works better than targeted therapies and chemotherapy, while also keeping quality of life high.
For: Metastatic Breast CancerGermany - RecruitingPHASE3
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
This study is testing a new drug called zoldonrasib, combined with standard chemotherapy, for people with pancreatic cancer that has spread. It compares this combination to chemotherapy alone, to see if it helps people live longer or stops the cancer from growing for longer. It focuses on a specific type of cancer gene.
For: Pancreatic Cancer · Pancreatic Cancer Metastatic · PDACUnited States · United Kingdom - RecruitingPHASE2, PHASE3
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
This study is looking into a new treatment called SBP-101 for advanced pancreatic cancer. It combines SBP-101 with standard chemotherapy (nab-paclitaxel and gemcitabine) to see if it helps people live longer and improves their quality of life.
For: Pancreatic Cancer Metastatic · Pancreatic Ductal Adenocarcinoma · Pancreatic Cancer Stage IVUnited States · Australia · Austria - RecruitingPHASE1
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
This study looks at a new drug, LY4050784, for advanced or metastatic solid cancers. We want to see if it's safe and effective, on its own or with other medicines, especially for cancers with a specific gene change called SMARCA4 (BRG1).
For: Metastatic Solid Tumor · Advanced Solid Tumor · Non-small Cell Lung CancerUnited States · France · Germany - Active not recruitingPHASE3
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
This study compares a new breast cancer drug, trastuzumab deruxtecan, with standard treatments. It's for people with HER2-low breast cancer that has spread or can't be removed by surgery and who have already had other treatments.
For: Breast CancerUnited States · Austria · Belgium - RecruitingPHASE2
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
This study looks at combining special medicines called immunotherapy with propranolol, and sometimes chemotherapy, for advanced pancreatic, liver, or bile duct cancers. It aims to see how safe and effective this new treatment approach is for patients.
For: Pancreatic Cancer · Hepatocellular Cancer · Biliary Tract CancerCanada - Active not recruitingPHASE2
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
This study is looking at a new combination of medicines - AZD0171, durvalumab, and standard chemotherapy - for people with advanced pancreatic cancer. It aims to see how safe and effective this new treatment is.
For: Locally Advanced or Metastatic Solid TumoursUnited States · Canada · South Korea - Active not recruitingPHASE3
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
This study is looking for a new treatment for pancreatic cancer that has spread. It compares a new medicine called RMC-6236 with standard chemotherapy for people whose cancer has already been treated once before. The aim is to see if the new medicine is safer and works better.
For: Pancreatic Cancer · PDAC · PDAC - Pancreatic Ductal AdenocarcinomaUnited States · France · Germany - Active not recruitingPHASE2
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
This study looks at new drug combinations to treat advanced lung cancer. It compares two different drug mixes, each including chemotherapy, to see which works best and is safest for people with Stage IV or recurrent non-small cell lung cancer.
For: Non-small Cell Lung Cancer · Recurrent Non-small Cell Lung Cancer · Metastatic Non-small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
This study looks at a new drug, DB-1303/BNT323, for advanced breast cancer that's 'HER2-low' and hormone-positive. It compares the new drug to standard chemotherapy to see if it can stop the cancer from growing for longer.
For: Metastatic Breast CancerUnited States · Argentina · Australia - Not yet recruitingPHASE2
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
This study is for people with advanced solid tumours that have a specific genetic change called an MTAP deletion. It's testing a new medicine, BMS-986504, alone and with other cancer treatments, to see how safe and effective they are.
For: Solid TumorsUnited States · Belgium · Canada - Active not recruitingPHASE4
Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
This study looks at new ways to treat advanced lung cancer that has spread. It compares two different drug combinations to see which works better for a specific type of lung cancer that doesn't have certain features.
For: Non-Small Cell Lung Cancer MetastaticGermany - Active not recruitingPHASE2
Study of Novel Treatment Combinations in Patients With Lung Cancer
This study looks at new drug combinations to treat lung cancer. It has three parts: for cancer that has spread, cancer that has grown despite previous treatment, and earlier-stage cancer that can be removed by surgery.
For: Lung Cancer · Advanced or Metastatic Non-Small-Cell Lung Cancer · Resectable Non-Small-Cell Lung CancerUnited States · Brazil · Hong Kong - Active not recruitingPHASE2, PHASE3
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
This study is looking at a new drug, Navlimetostat, combined with standard treatment (Nab-paclitaxel and Gemcitabine) for pancreatic cancer that has spread. It's for people whose cancer has a specific genetic change called MTAP deletion, which the new drug targets.
For: Pancreatic Ductal AdenocarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE2
A Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer
This study looks at a new combination of medicines for pancreatic cancer. It tests if adding a drug called ATRA to standard treatment (gemcitabine and nab-paclitaxel) helps patients with locally advanced pancreatic cancer not yet treated with other drugs. It's a randomised trial, meaning some get the new drug combo and some get the standard one.
For: Pancreatic CancerUnited Kingdom